Prophylactic cranial irradiation in lung cancer

Area of Science:

• Oncology
• Radiation Oncology
• Clinical Trials

Background:

• Brain relapse is a growing concern in lung cancer due to improved local control and reduced extracranial metastases.
• Survival rates are poor following the development of brain metastases, necessitating preventative strategies.

Purpose of the Study:

• To evaluate the efficacy of prophylactic cranial irradiation (PCI) in reducing brain metastases and improving survival in small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC).

Main Methods:

• Review of randomized trials evaluating PCI in SCLC and NSCLC.
• Analysis of data on brain metastasis (BM) rates and overall survival in different lung cancer subtypes and disease stages.

Main Results:

• PCI significantly reduces BM incidence in limited disease (LD) and extensive disease (ED) SCLC, and in non-metastatic NSCLC.
• PCI improves overall survival in SCLC patients (LD: 15% to 20% at 3 years; ED: 13% to 27% at 1 year) who respond to first-line treatment.
• The optimal dose for PCI in LD SCLC is 25Gy in 10 fractions; no dose-effect relationship was found.

Conclusions:

• PCI should be a standard treatment for SCLC responders, particularly in ED and good responders in LD.
• While NSCLC has a lower risk of brain dissemination, it remains a challenge, and PCI warrants reconsideration for high-risk subgroups.
• Further underpowered randomized trials are needed to establish PCI's survival benefit in NSCLC.